GLPwatch
Papers (10376)
Page 80 of 173, ranked by citation count.
- Maturity-Onset diabetes of the young type 5 treated with the glucagon-like peptide-1 receptor agonist: A case report.
- Exenatide improves glucocorticoid-induced glucose intolerance in mice.
- Liraglutide and the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first-episode psychosis: protocol for a pilot trial.
- Liraglutide improves depressive and cognitive deficits in a high-fat diet rat model of obesity: the role of hippocampal autophagy and the PI3K/Akt/mTOR pathway.
- Dermal Hypersensitivity Reaction to Semaglutide: Two Case Reports.
- No association between semaglutide and postoperative pneumonia in people with diabetes undergoing elective surgery.
- Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review and Meta-Analysis.
- Challenges Related to Glycemic Control in Type 2 Diabetes Mellitus Patients.
- Tirzepatide administration improves cognitive impairment in HFD mice by regulating the SIRT3-NLRP3 axis.
- Exendin-4 regulates GLUT2 expression via the CaMKK/CaMKIV pathway in a pancreatic β-cell line.
- Effect of once-weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD-2 clinical trial.
- Responsive oligochitosan nano-vesicles with ursodeoxycholic acid and exenatide for NAFLD synergistic therapy via SIRT1.
- Semaglutide for obesity: four STEPs forward, but more to come.
- Precision therapy for three Chinese families with maturity-onset diabetes of the young (MODY12).
- What is the evidence regarding the safety of new obesity pharmacotherapies.
- Modulatory effect of liraglutide on doxorubicin-induced testicular toxicity and behavioral abnormalities in rats: role of testicular-brain axis.
- Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE-2 study.
- Considering the use of GLP-1 receptor agonists in women with obesity prior to pregnancy: a narrative review.
- Real-world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus.
- The Effects of Exenatide Microsphere on Serum BGP and ALP Levels in ZDF Rats after Implantation.
- GLP-1-Exendin-4/IgG4 (Fc) fusion protein as a novel drug for diabetes treatment.
- Effect of Liraglutide on Serum TSH Levels in Patients with NAFLD and its Underlying Mechanisms.
- Lithocholic Acid-Based Peptide Delivery System for an Enhanced Pharmacological and Pharmacokinetic Profile of Xenopus GLP-1 Analogs.
- Lixisenatide reduces glycaemic variability in insulin-treated patients with type 2 diabetes.
- The cost-effectiveness of dulaglutide versus insulin glargine for the treatment of type 2 diabetes mellitus in Japan.
- Exenatide exerts a neuroprotective effect against diabetic cognitive impairment in rats by inhibiting apoptosis: Role of the JNK/c‑JUN signaling pathway.
- Effect of once-weekly subcutaneous semaglutide 2.4 mg on weight- and health-related quality of life in an East Asian population: Patient-reported outcomes from the STEP 6 trial.
- Brexpiprazole caused glycolipid metabolic disorder by inhibiting GLP1/GLP1R signaling in rats.
- Effectiveness of pharmacological interventions for managing obesity in children and adolescents: A systematic review and meta-analysis framed using minimal important difference estimates based on GRADE guidance to inform a clinical practice guideline.
- Effects of selenium and exendin-4 on glucagon-like peptide-1 receptor, IRS-1, and Raf-1 in the liver of diabetic rats.
- Current pharmacotherapies for obesity: A practical perspective.
- The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 Diabetes: a systematic literature review.
- Effect of Semaglutide on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults With Overweight and Insulin Resistance: Protocol for an Open-Labeled Randomized Controlled Trial.
- Insights into the central pathways involved in the emetic and behavioural responses to exendin-4 in the ferret.
- An Investigative Study of Pancreatic Exocrine Biomarkers, Histology, and Histomorphometry in Male Zucker Diabetic Fatty (ZDF) Rats Given Dulaglutide by Subcutaneous Injection Twice Weekly for 13 Weeks.
- A pilot clinical study to Evaluate Liraglutide-mediated Anti-platelet activity in patients with type-2 Diabetes (ELAID study).
- Liraglutide treatment in a patient with HIV and uncontrolled insulin-treated type 2 diabetes.
- Semaglutide in Psychiatry-Opportunities and Challenges.
- Potential role of tirzepatide towards Covid-19 infection in diabetic patients: a perspective approach.
- IDegLira fixed-ratio combination in the real world: a retrospective observational single-center Italian experience.
- Effect of hydroxyethyl starch on drug stability and release of semaglutide in PLGA microspheres.
- A systematic review on the efficacy of GLP-1 receptor agonists in mitigating psychotropic drug-related weight gain.
- Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study.
- Comparison of the effect of liraglutide and metformin therapy on the disease regulation and weight loss in obese patients with Type 2 diabetes mellitus.
- Design and methods of a randomised double-blind trial of adding liraglutide to control HbA1c in patients with type 2 diabetes with impaired glycaemic control treated with multiple daily insulin injections (MDI-Liraglutide trial).
- GLP-1 agonist liraglutide improves ouabain-induced mania and depressive state <i>via</i> GSK-3β pathway.
- Long-Term Efficacy and Safety of Nutritional and Pharmacological Strategies for Obesity.
- Fabrication of liraglutide-encapsulated triple layer hyaluronic acid microneedles (TLMs) for the treatment of obesity.
- Healthcare resource utilization and costs assessment of type 2 diabetes patients initiating exenatide BID or glargine: a retrospective database analysis.
- Semaglutide versus other GLP-1 receptor agonists in patients with MASLD.
- Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?
- Increased reporting of accidental overdose with glucagon-like peptide-1 receptor agonists: a population-based study.
- Targeted pH switched europium complexes monitoring receptor internalisation in living cells.
- Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting.
- Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program.
- Exendin-4 increases absence-like seizures and anxiety-depression-like behaviors in WAG/Rij rats.
- Italian guidelines for the management of adult individuals with overweight and obesity and metabolic comorbidities that are resistant to behavioral treatment.
- Euglycaemic diabetic ketoacidosis in a patient with type 2 diabetes started on empagliflozin.
- Exenatide once weekly for the treatment of type 2 diabetes mellitus: clinical results in subgroups of patients using different concomitant medications.
- One-year safety and efficacy results of insulin treatment simplification with IDegLira in type 2 diabetes.